Skip to main content

DNAPrint to Identify Genetic Markers for NYU Transplant Center

 

NEW YORK, Dec. 3 – DNAPrint Genomics of Sarasota, Fla., said Monday that it had entered an agreement with the New York University School of Medicine to identify genetic markers that can help determine how recipients of kidney transplants will respond to certain drugs. 

Under the terms of the deal, NYU's Mary Lea Johnson Richards Organ Transplantation Center will provide DNAPrint with patient samples and clinical data from patients. DNAPrint will use its genotyping technologies and SNP database to screen the specimens for markers. 

“The goal of the project is to identify pharmacogenomic classifiers that could be used to match renal transplantation patients with the optimal immunosuppressant for their genetic architecture,” DNAPrint said in a statement.

The company estimated that the project would take about one year to complete.

Financial terms of the deal were not disclosed.

In August, DNAPrint Genomics announced a deal to study specimens provided by Pharsight of Mountain View, Calif., to determine which genetic markers are responsible for patients' varying responses to drugs designed to treat metabolic disorders.

 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.